-
Oct.052022NEWS
HanAll’s Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner
HanAll’s Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partn..
-
Jul.292022NEWS
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
-
Apr.282022NEWS
HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update
HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update
-
Apr.112022NEWS
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiat..
-
Mar.142022NEWS
HanAll Biopharma Launches KRW 10 billion Share Buyback Program
HanAll Biopharma Launches KRW 10 billion Share Buyback Program
-
Feb.212022NEWS
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer